Clinuvel Pharmaceuticals (CUVL) Financial statements
Clinuvel Pharmaceuticals reported revenue of $64M in fiscal 2026, up 5.4% a year over 2 years.
Key figures
Net income was $23M and the operating margin 43.4%, against 49.3% in 2024. Free cash flow was $12M, and the company returned $2M in dividends.
- Revenue, FY2026
- $64M+5.2% on 2025
- Net income
- $23M+0.2% on 2025
- Operating margin
- 43.4%
- Free cash flow
- $12M-56.3% on 2025
Revenue and free cash flow
Fiscal years, from Clinuvel Pharmaceuticals's 10-K filings.
Clinuvel Pharmaceuticals revenue and free cash flow
FY2024–FY2026Margins
How much of each dollar of revenue is left after the cost of sales, after operating costs, and at the bottom line.
Clinuvel Pharmaceuticals margins
FY2024–FY2026Financial statements
Fiscal 2024–2026.
Clinuvel Pharmaceuticals income statement, fiscal 2024–2026
| USD | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | $58M | $61M | $64M |
| Cost of revenue | $11M | $12M | $11M |
| Gross profit | $47M | $50M | $53M |
| Research and development | $10M | $13M | $12M |
| Selling, general and admin | $7M | $7M | $7M |
| Operating income | $29M | $27M | $28M |
| Pre-tax income | $33M | $33M | $33M |
| Income tax | $10M | $10M | $10M |
| Net income | $23M | $23M | $23M |
| EPS (diluted) | $0.46 | $0.46 | $0.46 |
| Diluted shares | 51M | 50M | 51M |
| Gross margin | 81.5% | 81.2% | 82.9% |
| Operating margin | 49.3% | 43.4% | 43.4% |
| Net margin | 40.3% | 37.8% | 36.0% |
Clinuvel Pharmaceuticals balance sheet, fiscal 2024–2026
| USD | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Cash and short-term investments | $23M | $146M | $174M |
| Receivables | $18M | $18M | $16M |
| Inventory | — | $6M | $5M |
| Total current assets | — | $171M | $197M |
| Property, plant and equipment | — | $5M | $5M |
| Total assets | — | $177M | $204M |
| Total current liabilities | — | $18M | $13M |
| Long-term debt | — | $0 | $0 |
| Total liabilities | — | $20M | $15M |
| Shareholders' equity | $135M | $157M | $189M |
| Net debt | -$23M | -$18M | -$14M |
Clinuvel Pharmaceuticals cash flow, fiscal 2024–2026
| USD | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Operating cash flow | $24M | $27M | $13M |
| Capital spending | $4M | $190,593 | $1M |
| Free cash flow | $20M | $27M | $12M |
| Stock-based compensation | $4M | $1M | $2M |
| Dividends paid | $2M | $2M | $2M |
| Share buybacks (net) | -$497,659 | -$173,965 | — |
| Free cash flow margin | 34.7% | 44.3% | 18.4% |
| Dividends per share | $0.03 | $0.03 | $0.03 |
How Clinuvel Pharmaceuticals compares
Clinuvel Pharmaceuticals's operating margin is higher than 97% of Healthcare companies and 95% of the 2,821 companies with an operating margin figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Operating margin | 97% | 95% |
| Net margin | 96% | 94% |
| Gross margin | 81% | 93% |
| Revenue growth | 38% | 37% |
| ROE | 79% | 64% |
| P/E | 20% | 21% |
Questions about Clinuvel Pharmaceuticals
What was Clinuvel Pharmaceuticals's revenue in 2026?
$64M in fiscal 2026, from its 10-K filing.
How much free cash flow does Clinuvel Pharmaceuticals generate?
$12M in fiscal 2026 (operating cash flow minus capital spending).
From Clinuvel Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.